Zymeworks stock gains on merger approval and a $41 target

Zymeworks stock (ISIN CA98959U1084) closed at USD 26.57 on September 18, 2026, after a 3.31 percent drop, while MarketBeat put its market capitalization at USD 1.89 billion and the 52-week range at USD 15.81 to USD 31.34.

Merger vote adds a date

On September 18, 2026, shareholders of Theravance Biopharma approved proposals tied to the planned merger with Zymeworks, and the transaction is expected to close on or about September 23, 2026, according to The Globe and Mail. The report said 79.14 percent of outstanding ordinary shares were represented at the meeting, a level that helped clear a key closing condition.

That merger step matters because it adds a near-term corporate event to a stock that already traded with a wide range of USD 15.81 to USD 31.34 in the latest MarketBeat snapshot from September 19, 2026. The same page said Zymeworks had 1.10 million shares traded against an average volume of 756,597 shares and a consensus price target of USD 41.00.

Analyst target stays above price

MarketBeat also described Zymeworks as a Moderate Buy on September 19, 2026, with 10 buy ratings, 1 hold rating and 1 sell rating in its coverage summary. It put the upside to the consensus target at 54.3 percent, based on the USD 26.57 close.

For investors, the gap between USD 26.57 and USD 41.00 is the clearest market signal in the latest data set. The share price is still near the middle of its 52-week band, but the merger timetable now gives the name a concrete date to watch.

Stock near its range

As of September 18, 2026, Zymeworks stock was priced at USD 26.57 on Nasdaq, with a prior close of USD 27.48 and a daily change of minus 3.31 percent.

More news and analyses on Zymeworks stock